GLAXOSMITHKLINE PLC Form 6-K October 13, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 13 October 2017

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

a)	Details of PDMR/person closely associated with them ('PCA') Name Ms E Walmsley Position/status Chief Executive Officer		
0)	Position/status		
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a) b)	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence		
a)	Description of the financial instrument	each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2659 408.631	
d)	Aggregated information	n/a (single transaction)	
,	Aggregated volume Price		
e)	Date of the transaction	2017-10-12	
f)	Place of the transaction	London Stock Exchange (XLON)	
1.	Details of PDMR/person closely associat	ted with them ('PCA')	
a)	Name	Mr R G Connor	
b)	Position/status	President, Global Manufacturing & Supply	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
c)	place where transaction(s) has been cond		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2659 71.145	
d)	Aggregated information	n/a (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction Place of the transaction	2017-10-12 London Stock Exchange	
f)	Trace of the transaction	(XLON)	
1.	Details of PDMR/person closely associat		
,		Mr L Debruyne	
	Position/status	President, Global Vaccines	
C)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	-	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2659 735.251	
d)	Aggregated information	n/a (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2017-10-12	
f)	Place of the transaction	London Stock Exchange (XLON)	
1.	Details of PDMR/person closely associat		
a)	Name	Mr S Dingemans	
	Position/status	Chief Financial Officer	
C)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	

	Edgar Filing	: GLAXOSMITHKLINE PLC - Fo	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence		
a)	Description of the financial instrument	each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2659 793.924	
d)	Aggregated information	n/a (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2017-10-12	
f)	Place of the transaction	London Stock Exchange (XLON)	
	Details of PDMR/person closely associated with them ('PCA')		
	Name	Mr D S Redfern	
	Position/status Initial notification/ amendment	Chief Strategy Officer Initial notification	
	Details of the issuer, emission allowance		
2.	platform, auctioneer or auction monitor	market participant, adeiton	
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUŶLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2659 1,340.169	
d)	Aggregated information	n/a (single transaction)	
)	Aggregated volume Price		
e)	Date of the transaction	2017-10-12	
f)	Place of the transaction	London Stock Exchange (XLON)	

- 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms C Thomas SVP. HR b) Position/status c) Initial notification/ amendment Initial notification Details of the issuer, emission allowance market participant, auction 2 platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends b) Nature of the transaction paid to shareholders on 12 October 2017. Price(s) Volume(s) c) Price(s) and volume(s) £15.2659 517.830 Aggregated information n/a (single transaction) d) Aggregated volume Price e) Date of the transaction 2017-10-12 Place of the transaction London Stock Exchange f) (XLON) 1. Details of PDMR/person closely associated with them ('PCA') Mr P C Thomson a) Name President, Global Affairs b) Position/status c) Initial notification/ amendment Initial notification Details of the issuer, emission allowance market participant, auction 2 platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 a) Description of the financial instrument
- b) Nature of the transaction Shares following the re-investment of dividends paid to shareholders on 12

c)d)e)	Price(s) and volume(s) Aggregated information Aggregated volume Price Date of the transaction	October 2017 Price(s) £15.2659 n/a (single tra 2017-10-12	Volume(s) 628.735	
f)	Place of the transaction	London Stock Exchange (XLON)		
b) c)	Details of PDMR/person closely associat Name Position/status Initial notification/ amendment Details of the issuer amission allowance	Dr P J T Vall President, R& Initial notific	lance &D eation	
b)	platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to be	GlaxoSmithKline plc 5493000HZTVUYLO1D793 s of the transaction(s): section to be repeated for (i) each type of ment; (ii) each type of transaction; (iii) each date; and (iv) each where transaction(s) has been conducted		
a)	Description of the financial instrument	each ('Ordina ISIN: GB000	•	
b)	Nature of the transaction	paid to share October 2017	ving the t of dividends holders on 12 7.	
c)	Price(s) and volume(s)	Price(s) £15.2659	Volume(s) 2,519.628	
d)	Aggregated information	n/a (single tra	ansaction)	
e) f)	Aggregated volume Price Date of the transaction Place of the transaction	2017-10-12 London Stock Exchange (XLON)		
1. a)	Details of PDMR/person closely associat Name	ed with them Mrs K Thom		
b)	Position/status	ion/status PCA of Mr P C Thomson (President, Global Affairs) I notification/ amendment Initial notification Is of the issuer, emission allowance market participant, auction form, auctioneer or auction monitor		
c) 2.	platform, auctioneer or auction monitor			
a) b) 3.				

6

place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.	
c) Price(s) and volume(s)	Price(s) Volume(s) £15.2659 118.755	
Aggregated information d)	n/a (single transaction)	
Aggregated volume Price e) Date of the transaction Place of the transaction f)	asaction 2017-10-12	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: October 13, 2017

By: VICTORIA WHYTE-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc